Frontiers in Immunology · 2022 · 41 citations · 52 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint RegulationImmune CheckpointsAnti-cd20 TherapyAntibodiesCheckpoint Inhibitor AntibodiesCheckpoint Modulation In CancerCheckpoint Therapeutic AntibodiesHla Class I MoleculesMonoclonal Antibodies In OncologyRituximab-based Therapy
Antibody-dependent cellular phagocytosis (ADCP) by macrophages, an important effector function of tumor targeting antibodies, is hampered by 'Don´t Eat Me!' signals such as CD47 expressed by cancer cells. Yet, human leukocyte antigen (HLA) class I expression may also impair ADCP by engaging leukocyte immunoglobulin-like receptor subfamily B (LILRB) member 1 (LILRB1) or LILRB2. Analysis of different lymphoma cell lines revealed that the ratio of CD20 to HLA class I cell surface molecules determined the sensitivity to ADCP by the combination of rituximab and an Fc-silent variant of the CD47 antibody magrolimab (CD47-IgGσ). To boost ADCP, Fc-silent antibodies against LILRB1 and LILRB2 were generated (LILRB1-IgGσ and LILRB2-IgGσ, respectively). While LILRB2-IgGσ was not effective, LILRB1-IgGσ significantly enhanced ADCP of lymphoma cell lines when combined with both rituximab and CD47-IgGσ. LILRB1-IgGσ promoted serial engulfment of lymphoma cells and potentiated ADCP by non-polarized M0 as well as polarized M1 and M2 macrophages, but required CD47 co-blockade and the presence of the CD20 antibody. Importantly, complementing rituximab and CD47-IgGσ, LILRB1-IgGσ increased ADCP of chronic lymphocytic leukemia (CLL) or lymphoma cells isolated from patients. Thus, dual checkpoint blockade of CD47 and LILRB1 may be promising to improve antibody therapy of CLL and lymphomas through enhancing ADCP by macrophages.
52
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira Barkal, Rachel Brewer, Maxim Markovic et al. · Nature · 2019 · 1.4K citations
Life Sciences, Immunology, Oncology +14
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text
Life Sciences, Immunology, Oncology +17
Mark P. Chao, Ash A. Alizadeh, Chad Tang et al. · Cell · 2010 · 1.1K citations · Full text
Medicine, Immunology, Oncology +14
Engineered antibody Fc variants with enhanced effector function
Greg A. Lazar, Wei Dang, Sher Karki et al. · Proceedings of the National Academy of Sciences · 2006 · 794 citations · Full text